ArticleInternational journal of clinical oncology2022

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).

Akio Nakasya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.